OWP
ATXS

Old Well Partners’s Astria Therapeutics ATXS Stock Holding History

Old Well Partners’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,116
Closed -$65K – 34
2021
Q4 		$65K Hold
12,116
– – 0.04% 41
2021
Q3 		$107K Buy
+12,116
New +$116K 0.06% 38

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Old Well Partners's ATXS Position: Q1 2022 in Review

Old Well Partners sold out of Astria Therapeutics (ATXS) in Q1 2022, closing a stake of 12,116 shares — an estimated $65K sold.

Old Well Partners first reported a position in ATXS in Q3 2021 and held it in 2 quarters. The position peaked at $107K in Q3 2021. 33 funds tracked by Wall St. Rank hold ATXS as of Q1 2022.

  • Old Well Partners reported no remaining Astria Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Old Well Partners sold 12,116 Astria Therapeutics shares in Q1 2022, an estimated $65K.
  • Old Well Partners first reported a position in Astria Therapeutics in Q3 2021 and held it in 2 quarters.
  • Old Well Partners's Astria Therapeutics position peaked at $107K in Q3 2021.
  • 33 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2022.

Based on Old Well Partners's 13F filing for Q1 2022, filed 16 May 2022.